prikaz prve stranice dokumenta Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
  Preuzmi
PDF 3.3 MB
Znanstveni rad - Pregledni rad
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
European Archives of Oto-Rhino-Laryngology, 276 (2019), 5; 1275-1281. https://doi.org/10.1007/s00405-019-05387-8
Suton, Petar; Skelin, Marko; Rakušić, Zoran; Dokuzović, Stjepan; Lukšić, Ivica

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Suton, P., Skelin, M., Rakušić, Z., Dokuzović, S. i Lukšić, I. (2019). Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology, 276. (5), 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton, Petar, et al. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology, vol. 276, br. 5, 2019, str. 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, Petar, Marko Skelin, Zoran Rakušić, Stjepan Dokuzović i Ivica Lukšić. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology 276, br. 5 (2019): 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, P., et al. (2019) 'Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE', European Archives of Oto-Rhino-Laryngology, 276(5), str. 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton P, Skelin M, Rakušić Z, Dokuzović S, Lukšić I. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology [Internet]. 05.2019. [pristupljeno 10.11.2024.];276(5):1275-1281. doi: 10.1007/s00405-019-05387-8

P. Suton, M. Skelin, Z. Rakušić, S. Dokuzović i I. Lukšić, "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE", European Archives of Oto-Rhino-Laryngology, vol. 276, br. 5, str. 1275-1281, Svibanj 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:503286. [Citirano: 10.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:503286
Podaci o radu
Naslov (engleski)Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
AutorPetar Suton
AutorMarko Skelin
AutorZoran Rakušić
AutorStjepan Dokuzović
AutorIvica Lukšić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MAKSILOFACIJALNU KIRURGIJU SA STOMATOLOGIJOM)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Kirurgija
Sažetak (engleski)
Purpose: Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta-analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16-positive OPC. ----- Methods: A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients. ----- Results: The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 (P < 0.0001). The data from eight studies were available for the analysis of 2-year locoregional recurrence (LRR). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy was 0.35 (P < 0.0001). Patients receiving CDDP with irradiation had 2.2- and 2.9-fold decreased risk for death from any cause and LRR, respectively. ----- Conclusions: For patients with HPV-positive OPC, radiotherapy plus C225 showed inferior OS and higher LRR rates compared with radiotherapy plus CDDP. CDDP-based chemoradiotherapy should remain standard of definitive treatment of p16-positive OPC.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaEuropean Archives of Oto-Rhino-Laryngology
Brojčani podacivol. 276, br. 5, str. 1275-1281
p-ISSN0937-4477
e-ISSN1434-4726
DOIhttps://doi.org/10.1007/s00405-019-05387-8
URN:NBNurn:nbn:hr:105:503286
Datum objave publikacije2019-05
URL dokumentahttp://link.springer.com/10.1007/s00405-019-05387-8
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-03-17 11:20:20